TMC Life Sciences Q2 FY2026 profit jumps to RM6.6m; 1H profit quadruples on higher hospital revenue, cost efficiencies
Summary:
-
TMC Life Sciences (Thomson Medical Malaysia) posted Q2 FY2026 revenue of RM103.5m, up 29% year on year, with profit before tax swinging to RM9.3m from a RM0.5m loss; Q2 net profit was RM6.6m versus a RM0.9m loss.
-
For 1H FY2026, revenue rose 26% to RM204.0m and profit before tax more than quadrupled to RM15.9m from RM4.0m, driven by stronger contributions from key specialties and cost-efficiency initiatives at Thomson Hospital Kota Damansara.
-
1H net profit climbed to RM11.0m from RM2.0m, lifting basic EPS to 0.63 sen from 0.11 sen; net operating cash flow more than doubled to RM28.3m from RM12.1m, helping cash and bank balances rise to RM112.9m.
-
The Group’s net assets stood at RM860.8m as at 31 December 2025 (NAV per share: RM0.49), with total borrowings reduced to RM164.1m from RM179.5m at end-June 2025.
-
Management remains optimistic on FY2026, citing increased capacity, expansion across key specialties, stronger corporate and international patient flows and ongoing cost-efficiency measures, while flagging evolving reimbursement dynamics and payor pressure on affordability and value.